Mr. Michal Efraty reports

NEUROTHERA LABS ANNOUNCES PUBLICATION OF INTERNATIONAL PATENT IN COLLABORATION WITH CLEARMIND MEDICINE FOR NOVEL THERAPY TARGETING WEIGHT LOSS AND FATTY LIVER DISEASE

Neurothera Labs Inc. has advanced its collaboration with Clearmind Medicine Inc. with the publication of an international patent application under the Patent Cooperation Treaty (PCT) for a novel combination therapy aimed at treating weight loss and metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as fatty liver disease).

The patent publication highlights the potential of a 5-methoxy-2-aminoindane (MEAI)-Palmitoylethanolamide (PEA) combination to offer a safe, non-hallucinogenic neuroplastogen treatment for two major global health challenges: obesity, affecting over 890 million adults worldwide, and MASLD, impacting approximately 30 per cent of the global adult population.

Moreover, due to the presumed mechanism of action of the combination, this therapeutic option may offer a safer, easier and more cost-effective option than GLP-1s agonists for obesity and MASLD.

By combining Clearmind's MEAI platform with Neurothera's PEA, the companies wish to address the escalating demand for effective, tolerable and safe treatments in the obesity and liver health space. This comes at a time when the global weight-loss-drugs market is experiencing rapid growth, which was valued at approximately $37-billion in 2025 and is forecasted to reach $226-billion by 2035, driven by increasing awareness of obesity as a chronic disease and the need for innovative alternatives to GLP-1 agonists.

About Neurothera Labs Inc.

Neurothera Labs is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.

About Clearmind Medicine Inc.

Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder.

We seek Safe Harbor.